Gene Therapy in Oncology Market Report 2022: Featuring Amgen, BMS Gilead, Janssen Biotech, Novartis, Shanghai Sunway Biotech & Shenzen Sibiono GeneTech. - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Gene Therapy in Oncology Market Size, Share, Trends, Analysis and Forecast by Region, Segment, Therapy Type (Oncolytic Virotherapy, Gene Transfer, Gene Induced Immunotherapy) and End-user (Hospitals, Diagnostic Centers, Research Institutes), 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The gene therapy in oncology market size was valued at US$2045 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 23.7% during 2022-2027. The gene therapy in oncology market report provides an executive-level overview of the gene therapy in oncology market worldwide today, with detailed forecasts of key indicators up to 2027.

This market intelligence report offers a thorough, forward-looking analysis of the global gene therapy in oncology market, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.

The key to the growth has been the high prevalence of cancer and growing investment and funding for product development. Additionally, key strategic partnerships and mergers and acquisitions are expected to accelerate market growth. Over the forecast period, the market will witness an increase in government initiatives, favoring the gene therapy in oncology market growth.

Scope

• This report provides overview of addressable market for gene therapy in oncology market
• It identifies the key trends impacting growth of the market over the next 12 to 24 months, split into three categories: technology trends, macroeconomic trends, and regulatory trends.
• It includes global market forecasts for the gene therapy in oncology industry
• It include segmental forecasts and vendor snapshot on leading vendors operating in or the gene therapy in oncology industry

Reasons to Buy

• This market intelligence report offers a thorough, forward-looking analysis of the global gene therapy in oncology market and key opportunities in a concise format to help executives build proactive and profitable growth strategies.
• Accompanying the publisher's Forecast products, the report examines the assumptions and drivers behind ongoing and upcoming trends in gene therapy in oncology markets.
• The report also highlights key therapy type and end-user segments.
• With different charts and tables, the report is designed for an executive-level audience, boasting presentation quality.
• The report provides an easily digestible market assessment for decision-makers built around in-depth information gathered from market players, which enables executives to quickly get up to speed with the current and emerging trends in gene therapy in oncology markets.

Key Topics Covered:

CHAPTER 01 Executive Summary

CHAPTER 02 Research Scope and Segmentation

CHAPTER 03 Technology Briefing

CHAPTER 04 Gene Therapy in Oncology Industry Trends Analysis

CHAPTER 05 Global Gene Therapy in Oncology Revenue Opportunity

CHAPTER 06 Regulatory Overview

CHAPTER 07 Gene Therapy in Oncology Therapy Type Outlook

CHAPTER 08 Gene Therapy in Oncology End-User Outlook

CHAPTER 09 Gene Therapy in Oncology Regional Outlook

CHAPTER 010 Trends, Drivers, and Challenges

CHAPTER 011 Global Gene Therapy in Oncology Competitive Landscape

CHAPTER 012 Appendix

Companies Mentioned

• Amgen
• BMS
• Gilead (Kite Pharma, Inc.)
• Janssen Biotech, Inc.
• Novartis
• Shanghai Sunway Biotech
• Shenzen Sibiono GeneTech

Source: GlobalData

For more information about this report visit https://www.researchandmarkets.com/r/mdi4pu